Related Experiment Videos
Temporal sequence and cellular origin of interleukin-2 stimulated cytokine gene expression
1Biological Therapy Laboratory, Imperial Cancer Research Fund, Lincoln's Inn Fields, UK.
Abstract:
A study of activation of the cytokine network by interleukin 2, IL-2, may provide a rationale for devising cytokine combination and cytokine antagonist treatments with increased anti-tumour efficacy and decreased toxicity. We have investigated the expression of mRNA for 13 cytokines and three transcription factors during in vitro culture of peripheral blood mononuclear cells, PBMC, with IL-2. A consistent pattern of induction was seen in nine individuals, with early (2-24 h) induction of IL-1 beta, IL-6, tumour necrosis factor, TNF, lymphotoxin, LT, and gro. TNF and LT mRNA was expressed continually throughout culture, but levels of mRNA for IL-1 beta, IL-6, and gro declined by 24-48 h. After 48 h, PBMC began to express mRNA for IFN-gamma, IL-5, GM-CSF, and M-CSF. At 15 min to 1 h post IL-2 mRNA for c-fos, c-jun, and c-myc, and TNF was induced in three individuals studied. IL-4, IFN-alpha, and IL-1 alpha mRNA was not detected. Only a minority of cells expressed mRNA for TNF, IL-1 beta, IL-6 and IFN-gamma, and monocytes were the main source. Levels of cytokine protein in culture supernatants mirrored the pattern of mRNA induction. This in vitro model shows clear parallels with the reported in vivo production of cytokines during IL-2 therapy, and may prove useful in designing new therapeutic strategies.
Insights
Interleukin 2 (IL-2) activates a cytokine network in peripheral blood mononuclear cells (PBMC). This study reveals patterns of cytokine gene expression, offering insights for novel cancer therapies.
Area of Science:
- Immunology
- Molecular Biology
- Cancer Research
Background:
- Interleukin 2 (IL-2) plays a crucial role in immune responses.
- Understanding the cytokine network activated by IL-2 is key for developing effective cancer treatments.
- Cytokine-based therapies aim to enhance anti-tumour efficacy while minimizing toxicity.
Purpose of the Study:
- To investigate the expression patterns of various cytokines and transcription factors in peripheral blood mononuclear cells (PBMC) upon stimulation with IL-2 in vitro.
- To establish a model for cytokine network activation that parallels in vivo responses during IL-2 therapy.
- To identify potential targets and strategies for novel combination cytokine and cytokine antagonist treatments.
Main Methods:
- In vitro culture of peripheral blood mononuclear cells (PBMC) with IL-2.
- Analysis of mRNA expression for 13 cytokines (including IL-1 beta, IL-6, TNF, LT, IFN-gamma, IL-5, GM-CSF, M-CSF) and three transcription factors (c-fos, c-jun, c-myc) at various time points.
- Detection of cytokine protein levels in culture supernatants.
- Identification of specific cell types (monocytes) expressing cytokine mRNA.
Main Results:
- A consistent pattern of cytokine mRNA induction was observed across nine individuals.
- Early induction (2-24 h) of IL-1 beta, IL-6, TNF, LT, and gro mRNA was noted.
- Later induction (after 48 h) of IFN-gamma, IL-5, GM-CSF, and M-CSF mRNA was detected.
- Rapid induction of c-fos, c-jun, c-myc, and TNF mRNA occurred within 15 min to 1 h in some individuals.
- Monocytes were identified as the primary source of mRNA for several key cytokines.
- Cytokine protein levels in supernatants correlated with mRNA expression patterns.
Conclusions:
- The in vitro PBMC model effectively mimics in vivo cytokine production during IL-2 therapy.
- The identified cytokine expression patterns provide a basis for designing improved therapeutic strategies.
- This research supports the development of targeted cytokine combination therapies and antagonists for enhanced anti-tumour activity and reduced side effects.